Skip to main content
. 2003 Oct 15;23(28):9374–9384. doi: 10.1523/JNEUROSCI.23-28-09374.2003

Figure 3.

Figure 3.

The CB1 antagonist SR141716A, administered systemically, attenuates both the stimulatory and inhibitory effects of WIN55,212-2 on ACh efflux in the hippocampus. Systemic administration of SR141716A [0.1 mg/kg, i.p.; administered simultaneously with WIN55,212-2 (arrow)] attenuated the stimulatory effects of WIN55,212-2 (0.5 mg/kg) (a) (F(10,90) = 2.4; p < 0.05; three-way ANOVA) and the inhibitory effects of WIN55,212-2 (5 mg/kg) (b) (F(10,70) = 2.06; p < 0.05; three-way ANOVA) on ACh efflux in the hippocampus. Data (expressed as fold over baseline established before any treatment) represent mean ± SEM of n = 4-6 animals per group. *p < 0.05 and **p < 0.01 for animals treated with SR141716A and WIN55,212-2 versus animals treated with WIN55,212-2 only, at each time point.